Shineco Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jennifer Zhan

İcra Kurulu Başkanı

US$73.4k

Toplam tazminat

CEO maaş yüzdesi	78.3%
CEO görev süresi	3.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.7yrs
Yönetim Kurulu ortalama görev süresi	3.2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jennifer Zhan'un ücretlendirmesi Shineco'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$30m
Jun 30 2024	US$73k	US$58k	-US$31m
Mar 31 2024	n/a	n/a	-US$14m
Dec 31 2023	n/a	n/a	-US$14m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	US$70k	US$60k	-US$10m
Mar 31 2023	n/a	n/a	US$2m
Dec 31 2022	n/a	n/a	US$2m
Sep 30 2022	n/a	n/a	US$2m
Jun 30 2022	US$70k	US$60k	-US$8m

Tazminat ve Piyasa: Jennifer 'nin toplam tazminatı ($USD 73.41K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 647.72K ).

Tazminat ve Kazançlar: Jennifer şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jennifer Zhan (36 yo)

3.3yrs

Görev süresi

US$73,408

Tazminat

Ms. Jennifer Zhan has been Chief Executive Officer of Shineco, Inc. since July 15, 2021 and has been its Executive Director since July 14, 2021. She was a founding partner of Tian ‘Ang capital Beijing Inve...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jennifer Zhan	CEO & Executive Director	3.3yrs	US$73.41k	Veri yok
Sai Wang	CFO & Director	9.8yrs	US$98.00k	0.50% $ 22.2k
Xiqiao Liu	COO & Executive Director	2.7yrs	US$10.00k	0% $ 0
Wang Xiaohui	Executive President	less than a year	Veri yok	Veri yok
Fenming Liu	Chief Scientist	no data	Veri yok	Veri yok
Qiyin Sun	Chief Medical Consultant	2.8yrs	Veri yok	Veri yok
Chi Keung Yan	Chief Strategy Officer	less than a year	Veri yok	Veri yok

2.7yrs

Ortalama Görev Süresi

45yo

Ortalama Yaş

Deneyimli Yönetim: SISI 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jennifer Zhan	CEO & Executive Director	3.3yrs	US$73.41k	Veri yok
Sai Wang	CFO & Director	8.4yrs	US$98.00k	0.50% $ 22.2k
Xiqiao Liu	COO & Executive Director	2.7yrs	US$10.00k	0% $ 0
Aamir Quraishi	Independent Director	2.3yrs	US$10.00k	Veri yok
Hu Li	Independent Director	3.2yrs	US$10.00k	Veri yok
Mike Zhao	Independent Chairman of the Board	3.3yrs	US$10.00k	Veri yok
Mingyong Hu	Independent Director	less than a year	Veri yok	Veri yok

3.2yrs

Ortalama Görev Süresi

46yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SISI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.2 yıldır).

Shineco Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Shineco, Inc., Annual General Meeting, Oct 21, 2024

Shineco, Inc., Annual General Meeting, Feb 01, 2024

Shineco, Inc. Announces the Appointment of Two New Executive Officers

Shineco, Inc., Annual General Meeting, Jun 28, 2023

High number of new and inexperienced directors

Shineco, Inc. Appoints Aamir Ali Quraishi as Independent Director

Recent updates

Market Cool On Shineco, Inc.'s (NASDAQ:SISI) Revenues

First quarter 2025 earnings released: US$2.34 loss per share (vs US$26.50 loss in 1Q 2024)

New major risk - Financial position

Full year 2024 earnings released: US$5.89 loss per share (vs US$5.43 loss in FY 2023)

Shineco, Inc., Annual General Meeting, Oct 21, 2024

Shineco Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Requirement

Shanchun Huang Engages in Discussions with Shineco

Shanchun Huang Engages in Discussions with Shineco

Shineco, Inc. has filed a Follow-on Equity Offering.

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shineco Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Requirement Under Nasdaq Listing Rule 5550(a)(2)

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

New major risk - Financial position

Shineco, Inc., Annual General Meeting, Feb 01, 2024

Shineco, Inc. Announces the Appointment of Two New Executive Officers

New major risk - Share price stability

New major risk - Financial position

Full year 2023 earnings released: US$0.54 loss per share (vs US$2.60 loss in FY 2022)

Shineco Not Regains Compliance with the Nasdaq's Minimum Bid Price Requirement

Shineco, Inc.'S Subsidiary, Changzhou Biowin Pharmaceutical Co., Ltd., Receives Marketing Approval from China's Regulatory Body for Its Cardiac 5 Minute Test

New major risk - Market cap size

Shineco, Inc., Annual General Meeting, Jun 28, 2023

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.30 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.32 loss in 2Q 2022)

Shineco, Inc. (NasdaqCM:SISI) signed a letter of intent to acquire 80% stake in Dream Partner Limited for $40 million.

First quarter 2023 earnings released: US$0.17 loss per share (vs US$1.34 loss in 1Q 2022)

High number of new and inexperienced directors

Shineco Receives Deficiency Letter from Nasdaq

Full year 2022 earnings released: US$2.60 loss per share (vs US$4.73 loss in FY 2021)

Shineco, Inc. Appoints Aamir Ali Quraishi as Independent Director

Shineco, Inc. Resigns Yanzeng as Member of the Board of Directors

High number of new and inexperienced directors

Shineco, Inc. Announces Management Changes

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Shineco, Inc. Appoints Qiyin Sun as Chief Medical Consultant

High number of new directors

Shineco, Inc. (NasdaqCM:SISI) entered into an agreement to acquire 51% stake in Xiang Peng You Kang (Beijing) Technology Co., Ltd.

Independent Director Harry Edelson has left the company

High number of new directors

Third quarter 2021 earnings released: US$2.36 loss per share (vs US$1.26 loss in 3Q 2020)

Shineco CEO steps down, new CEO appointed

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding terms of proposal to acquire a 51% stake in Mayah Biological Holdings Limited.

Shineco rallies on proposal to acquire 51% equity interests in Mayah Biological

Shineco, Inc. announced delayed 10-Q filing

New 90-day high: US$4.15

New 90-day high: US$3.82

New 90-day high: US$3.31

First quarter 2021 earnings released: US$0.35 loss per share

Full year earnings released - US$2.25 loss per share

New 90-day low - US$2.71

Shineco, Inc. Announces Management Changes

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding Letter of Intent to acquire 73.7% stake in Changzhou Biowin Pharmaceutical Co., Ltd from Beijing Kanghuayuan Technology Development Co., Ltd and Changzhou Kelinbo Venture Capital Partnership (limited partnership) for $25 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş